JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM, L3
Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business
Condensed Consolidated Interim Financial Statements As of June 30, 2026
Announces ADS Ratio Change Effective August 21, 2026
Holds Annual Meeting of Shareholders
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Announces Notice to Shareholders Regarding Proxy Statement for Annual General Meeting Scheduled for June 16, 2026
Notice of Annual General Meeting of Shareholders to Be Held on June 16, 2026
Pro Forma Consolidated Statement of Financial Position As of December 31, 2025
Annual and Transition Report of Foreign Private Issuers
Q1
FY 2022
Notice of Late Filing for Annual Report
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities of Certain Foreign Private Issuers
No filings found
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Post-Effective Amendment to Registration Statement
Submission Upload
Correspondence
NT 20-F